Elanco Animal Health Incorporated (ELAN) Earnings
Elanco Animal Health Incorporated is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $0.28. ELAN has beaten EPS estimates in 9 of its last 12 reported quarters (average surprise -127.8% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 6, 2026 | $0.34 | $0.40 | +17.6% | $1.4B | +7.4% |
| Feb 24, 2026 | $0.11 | $-0.56 | -604.9% | $1.1B | -10.4% |
| Nov 5, 2025 | $0.13 | $0.19 | +46.2% | $1.1B | +4.1% |
| Aug 7, 2025 | $0.20 | $0.26 | +30.0% | $1.2B | +13.9% |
| Feb 25, 2025 | $0.16 | $0.14 | -12.5% | $1.0B | -15.7% |
| Nov 7, 2024 | $0.12 | $0.13 | +8.3% | $1.0B | +1.7% |
| Aug 8, 2024 | $0.24 | $0.30 | +25.0% | $1.2B | +2.8% |
| Feb 26, 2024 | $0.10 | $0.08 | -20.0% | $1.0B | +3.3% |
| Feb 21, 2023 | $0.13 | $0.19 | +46.2% | $988M | +0.7% |
| Feb 24, 2022 | $0.17 | $0.21 | +23.5% | $1.1B | +0.8% |
| Nov 5, 2021 | $0.17 | $0.19 | +11.8% | $1.1B | +2.2% |
| May 7, 2021 | $0.23 | $0.37 | +60.9% | $1.2B | +7.4% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 6, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Jeff Simmons mentioned Elanco's first quarter organic constant currency revenue growth of 10%, outperforming guidance high ends. Innovation products generated $287 million in Q1 revenue, and the full-year innovation target was raised to $1.2 billion. Bob Van Himbergen discussed adjusted measures, including revenue, adjusted EBITDA, and adjusted EPS, and the progress of Elanco Ascend initiative to optimize cost structure and drive operational efficiencies.
Guidance
Full-year organic constant currency revenue growth expected to be 5%-7%, adjusted EBITDA $975 million to $1.005 billion, adjusted EPS $1.03 to $1.09. Second quarter expected to have $1.3 billion to $1.325 billion in revenue, organic constant currency revenue growth 4%-6%, adjusted EBITDA $240 million to $260 million, and adjusted EPS $0.25 to $0.28. Net leverage target for year-end revised to 3.0 to 3.2 times.
Segment performance
U.S. pet health achieved 6% organic constant currency revenue growth in Q1, with a sharp recovery in March to 8% growth and even better in April. Zenrelia was a major growth driver, and the retail OTC parasiticides business saw high single-digit consumption growth with new retailers like Costco and Dollar General. International pet health delivered 9% organic constant currency revenue growth driven by Xenrelia, AdTab, and Credelio. U.S. farm animal was up 15% in organic constant currency with good growth across all species and product categories. International farm animal was up 13% in organic constant currency, with poultry and ruminants as major contributors, and the favorable timing of customer purchases in the Middle East contributed one percentage point of growth for the total company.
Risks & headwinds
Heard competitive pressures including generics and consumer-level economic shifts could move results toward the lower end of expectations, while continued acceleration in innovation pipeline, underlying strength from base business, and leverage of diverse portfolio could drive results toward the high end.
Analyst Q&A
Q: John Block asked about U.S. pet health performance and drivers for 2H26 acceleration.
A: Jeff Simmons responded about rebound in March and April, contributions from Zenrelia, Quattro, Befrenta launch, price increase, and corporate accounts.
Q: Michael Riskin inquired about Zenrelia's success despite label restrictions and FDA label update timing.
A: Jeff Simmons talked about Zenrelia's strong efficacy, global momentum, and ongoing dialogue with FDA for additional data.
Q: Uma Rafat asked about farm business dynamics.
A: Jeff Simmons discussed protein revolution, growth in cattle, poultry, dairy, and the impact of HV acquisition.
Q: Brandon Vasquez asked about US pet health year-over-year and competition in guidance.
A: Jeff Simmons addressed year-over-year dynamics and balanced approach to competition in forecasting.
Q: Daniel Clark asked about clinic penetration for Zenrelia and Quattro.
A: Jeff Simmons highlighted clinic penetration, share within clinics, and market growth.
Q: Christopher Scott asked about reinvestment of upside and Vifrena feedback.
A: Jeff Simmons talked about reinvestment in innovation products and positive feedback on Vifrena.
Q: Stephen Deckard asked about vet visit volumes and Vifrena milestones.
A: Jeff Simmons mentioned vet visits not a determinant and Vifrena's milestones.
Q: Navon Tai asked about Bifrena strategy and farm MSAs.
A: Jeff Simmons discussed Bifrena's strategy and MSA outlook.
Q: Daniel Grossleit asked about capital deployment and retail partnerships.
A: Jeff Simmons talked about capital allocation priorities and retail partnership revenue and margin impact